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Summary
Objective: To clarify clinical and microbiological features of invasive group B Streptococcus
(GBS) disease in Japan.
Methods: This was a retrospective review for the period 1998—2007 of patients across all age
groups in Nishi-Kobe Medical Center. Invasive GBS disease was defined as GBS isolation from a
normally sterile site or skin/soft tissues.
Results: Six infant and 52 adult cases of invasive infection were identified. Diagnosis was limited
to bacteremia and meningitis in infants, but varied widely in adults with skin/soft tissue
infections and bacteremia being common. The overall fatality rate was 16%. An approximately
2.8-fold increase was found in the incidence among adult patients from the first to the second 5-
year period. The most frequent underlying condition was diabetes, with the majority (18/23) of
such patients showing poor control (HbA1c >8.0%). Amputation at the knee, ankle, or toes was
performed in six diabetic adults with skin/soft tissue infections. Of the strains serotyped, types Ib
and III predominated. All 58 strains were susceptible to penicillin; 2% were resistant to
erythromycin and 3% were resistant to clindamycin.
Conclusion: This is the first epidemiological report describing invasive GBS disease in Japan. A
significant increase in adult patients was noted, and mortality and morbidity remain substantial.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Group B Streptococcus (GBS), Streptococcus agalactiae, is a
major cause of sepsis andmeningitis in neonates, and also has
the ability to cause a wide variety of diseases in adulthood.1* Corresponding author. Tel.: +81 78 997 2200; fax: +81 78 993 3728.
E-mail address: kskmatsu@s4.dion.ne.jp (K. Matsubara).
1201-9712/$36.00 # 2008 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2008.10.007In both pediatric and adult populations, invasive GBS infec-
tion is associated with high mortality and morbidity.1 In the
USA, perinatal preventive practices based on intrapartum
chemoprophylaxis have led to a significant decrease in the
incidence of early-onset neonatal GBS infection.2 In contrast,
recent population-based series in the USA and Europe have
shown significant increases in the incidence in non-pregnant
adults.3—7Published by Elsevier Ltd. All rights reserved.
Figure 1 Annual change in patient numbers (closed column)
and incidence (solid line) of invasive group B streptococcal
disease in adult patients.
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characteristic of GBS epidemiology in Japan. First, sero-
types VI and VIII are the predominant strains isolated from
the vagina of pregnant women8 and, to a lesser extent,
from neonatal invasive GBS disease.9 These serotypes
have rarely been encountered in countries outside Japan.
Second, the incidence of early-onset and late-onset GBS
neonatal diseases in Japan is estimated to be much lower
than the incidences in the USA and Europe. A recent
multicenter study showed that the rate of early-onset
disease was 0.10/1000 live births (95% CI 0.04—0.15/
1000).10 Except for these reports, few data are available
on invasive GBS disease in Japan, especially on that occur-
ring in adults. Elucidation of such epidemiological data
is crucial for assessing the burden of the disease,
making rational decisions on preventive strategies, and
assessing the serotype distribution and impact of antimi-
crobial resistance. To provide this information, we report
herein a series of 58 cases of invasive GBS disease from
neonates to adults at a single institution, for the period
1998—2007.
Materials and methods
Study setting and subjects
Nishi-Kobe Medical Center is a tertiary hospital covering a
population of approximately 500 000, with all services,
including obstetrics and gynecology, pediatrics, and emer-
gency departments. The mean annual hospital admission
during the study period was 9313 patients, of whom 1131
were children aged less than 15 years. Patients diagnosed
with invasive GBS infections between January 1, 1998 and
December 31, 2007 were identified retrospectively. Inva-
sive GBS disease was defined as isolation of S. agalactiae
from a normally sterile site. Patients with skin and
soft tissue infections such as non-necrotizing bacterial
cellulitis, necrotizing fasciitis, and intramuscular
abscess caused by S. agalactiae were also included.3—5
Cellulitis was defined as extended well-demarcated
erythema with an acute onset of fever. Necrotizing fasciitis
was limited to cases in which necrotic changes were
pathologically confirmed in materials obtained during sur-
gery or autopsy. We excluded patients with diabetic foot
ulcer without fever or localized cutaneous abscesses.
Osteomyelitis was determined using magnetic resonance
imaging.
Microbiology tests
Susceptibility to antimicrobial agents was determined by
the microdilution method recommended by the Clinical
and Laboratory Standards Institute.11 Serotype was deter-
mined using a commercially available kit (Denka Seiken,
Tokyo).
Statistical analysis
Differences in the proportion of two groups were examined
with Chi-square analysis. The relationship between the
patient number and study year was calculated by Pearson’s
correlation test. Significance was established at p < 0.05.Results
Demographic features of subjects
We identified 58 cases of invasive GBS infections in 57
patients over the 10-year study period. Of these 57 patients,
six were neonates and infants aged between 0 and 89 days;
one was early-onset GBS disease vertically transmitted from
a GBS-carrier mother, and the remaining five were late-onset
GBS disease. Fifty-two infectious cases (90% of total epi-
sodes) in 51 patients occurred in adults (male:female,
27:24). There was no infection with GBS associated with
pregnant women. Non-pregnant adults with GBS disease
ranged in age from 29 to 90 years with a mean of 62 years.
Thirty-one (60%) of the adult infections occurred in the
elderly, aged 60 years or older.
The recurrent episode was identified in a 39-year-old male
patient with poorly controlled type 1 diabetes mellitus. He
developed muscle abscess and necrotizing fasciitis in the
right thigh, and subsequently developed abscess in the dorsal
region of the right foot with 5th metatarsal osteomyelitis.
These two episodes were two years apart.
Annual change in the incidence
The annual change in the incidence of GBS disease in adults is
shown in Figure 1. The patient number increased significantly
over the 10-year-period ( p < 0.0001, correlation coefficient
0.91). This trend remained significant ( p = 0.0002, correla-
tion coefficient 0.89) after adjusting for the annual number
of hospital admissions of patients aged over 15 years
(Figure 1). An approximately 2.8-fold (95% CI 1.5—5.4-fold)
increase was found in patient number from the first 5-year
period (1998—2002, 12 patients/34 723 hospital admissions)
to the second 5-year period (2003—2007, 40 patients/40 793
hospital admissions). Next, we analyzed separately the tem-
poral change in the incidence between adult patients with
GBS isolation from sterile sites (n = 26) and those with iso-
lation from non-sterile skin/soft tissue infections (n = 26).
The increase in incidence was more prominent among the
groups of skin/soft tissue infections (3.6-fold, 5/34 723 hos-
pital admissions in 1998—2002 vs. 21/40 793 hospital admis-
sions in 2003—2007) than among groups showing sterile site
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2002 vs. 19/40 793 hospital admissions in 2003—2007).
For the neonates and infants, there were two patients in
1998, one in 2000, two in 2006, and one in 2007. Although the
numbers were limited, there was no apparent increasing
trend in pediatric patients.
Clinical diagnosis
Clinical diagnoses are shown in Table 1. Of the six infants, two
(one early-onset and one late-onset infection) showed bac-
teremia without focus, and four had meningitis (all late-
onset disease). Of 52 adult cases, skin/soft tissue infection
was the most common presentation (n = 26, 50%). GBS was
isolated from any existing wound or aspirated abscess from
the affected skin/soft tissue in this type of infection. Of
these, 19 had diabetes mellitus and four were complicated by
osteomyelitis in the toe(s). Skin/soft tissue infections pre-
sented as cellulitis (leg n = 8, toe(s) n = 4, perianal region
n = 3, hand n = 1, foot n = 1, shoulder n = 1, nuchal region
n = 1), decubitus (back n = 2, hip n = 1), necrotizing fasciitis
(leg n = 1, scrotum and perianal region n = 1), and intramus-
cular abscess (thigh n = 1, hip n = 1). Bacteremia was the next
most common diagnosis (n = 19, 37%); among these, no focus
was identified in 12 patients, while the remaining seven
showed urinary tract infection (urosepsis; n = 3), arterial
valve endocarditis (n = 1), pericarditis with cardiac tampo-
nade (n = 1), cellulitis in the shoulder (n = 1), and toxic
shock-like syndrome and scrotal necrotizing fasciitis
(n = 1). Further sites of GBS isolation included cerebrospinalTable 1 Clinical diagnosis of invasive group B Streptococcus infe
Infants (n = 6)
Early-onset disease Bacte
Late-onset disease Bacte
Menin
Adult cases (n = 52)
Skin/soft tissue infection
Cellu
Decub
Necro
Intram
Bacteremia
Witho
Urose
Endoc
Peric
Cellu
Necro
Intra-abdominal infection
Ovari
Perito
Central nervous system infection
Menin
Subdu
Deep neck infection
TSLS, toxic shock-like syndrome.
a Of these 19, four cases were complicated by osteomyelitis.fluid (n = 2), and intra-operative aspirated pus from ovarian
abscess (n = 2), ascites (n = 1), retropharyngeal abscess
(n = 1), and subdural abscess (n = 1).
Four adult patients appeared to have acquired infection
nosocomially; their infections were recognized 10—92 days
after admission. Possible predisposing conditions associated
with these infections included indwelling central venous
catheter for cancer therapy (nosocomial infections: one
bacteremia without focus and one bacterial meningitis),
diabetes and long-term bedridden during treatment for
empyema (decubitus, n = 1), and neurosurgery for subdural
hematoma (bacterial meningitis, n = 1).
In 14 patients, GBS was one of the polymicrobial patho-
gens isolated. All patients were adults, and the majority
(n = 13) of cases were associated with soft tissue infection.
The most common concomitant pathogens were staphylo-
cocci (n = 9), followed by streptococci other than GBS (n = 3)
(Table 2).
Underlying conditions
Forty-eight of 52 adult cases who developed GBS infections
had various underlying conditions. The most common comor-
bid condition was diabetes mellitus (n = 25). To analyze the
status of diabetes control, we reviewed the glycated stable
hemoglobin (HbA1c) level of the diabetic patients at diag-
nosis of the GBS disease (n = 23). Of importance is that the
majority of these patients showed poor glycemic control; 18
diabetic patients (78%) showed an HbA1c level of 8.0%
or more (mean 10.0%, range 5.7—13.6%). Other commonctions.
Number
remia without focus 1
remia without focus 1
gitis 4
26
litis 19a
itus 3
tizing fasciitis 2
uscular abscess 2
19
ut focus 12
psis 3
arditis 1
arditis 1
litis 1
tizing fasciitis + TSLS 1
3
an abscess 2
nitis and abdominal abscess 1
3
gitis 2
ral abscess 1
1
Table 2 Additional organisms isolated from 14 patients with
invasive group B streptococcal disease.
Diagnosis Organism Number
Bacteremia 1
MSSA 1
Non-bacteremia 13
Staphylococci
MSSA 5
MRSA 2
Coagulase-negative
Staphylococcus
2
Other streptococci
Viridans Streptococcus 2
Group G Streptococcus 1
Klebsiella pneumoniae 1
MSSA, methicillin-sensitive Staphylococcus aureus; MRSA, methi-
cillin-resistant Staphylococcus aureus.
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failure (n = 9), and liver cirrhosis (n = 6).
Prognosis
The overall fatality rate was 9/58 (16%), which consisted of
1/6 infant cases (17%) and 8/52 adult cases (15%). In adults,
patients with bacteremia (7/19, 37%) showed a significantly
greater association ( p = 0.043) with fatal outcome compared
with those without bacteremia (1/32, 3%). All eight adult
patients who died had some underlying condition, and six of
eight patients were aged 60 years or older. However, neither
age nor presence of underlying condition was significantly
associated with fatality, nor was there any apparent associa-
tion between polymicrobial infection and fatality. Major
complications in survivors included mental retardation in
three infants with meningitis and amputation at the knee,
ankle, or toes in six diabetic adults with skin/soft tissue
infections.
Serotype distribution
Serotype was examined in 19 (33%) of the 58 GBS infections in
this series. The serotype distribution was as follows: Ia (n = 2;
2 infants, 0 adults), Ib (n = 6; 1 infant, 5 adults), III (n = 5; 1
infant, 4 adults), VI (n = 1; 0 infants, 1 adult), VII (n = 1; 0
infants, 1 adult), VIII (n = 2; 1 infant, 1 adult), and untypeable
(n = 2; 1 infant, 1 adult). Clinical profiles of GBS infections by
rare serotypes VI, VII, and VIII have been described. Type VI
caused a toxic shock-like syndrome followed by scrotal
necrotizing fasciitis in a 56-year-old diabetic patient.12 Type
VII caused meningitis in a 66-year-old male during treatment
for advanced gastric cancer with a fatal outcome. Type VIII
strains were isolated from the blood of a neonate with early-
onset disease13 and that of an 84-year-old female with
scleroderma complicated by burn.
Antimicrobial susceptibility
Antimicrobial susceptibility was analyzed for all 58 strains.
All strains were susceptible to penicillin G, ampicillin, cefo-
tiam, cefotaxime, and vancomycin. One (2%), two (3%), and18 (31%) strains were resistant to erythromycin, clindamycin,
and levofloxacin, respectively. Nine strains were intermedi-
ately susceptible to clindamycin.
Discussion
In Japan, invasive GBS disease among infants in the first three
months (early-onset and late-onset disease) has been inves-
tigated by a national surveillance for two decades.9 In con-
trast, there has been no similar review of invasive GBS
infections in adults. This is the first study describing clinical
and microbiological features of invasive GBS disease across
all age groups in Japan.
Our findings show that adult patients accounted for
approximately 90% of the total patients. Compared to recent
reports from the USA and Europe, where the proportion of
adult patients has ranged from 47% to 83%,6—8,14,15 our figure
is the highest reported. There are at least two explanations
for this high proportion. First, a recent multicenter study in
Japan indicated that the incidence of early-onset and late-
onset disease among infants is relatively lower than that
found in other countries.10 Our previous work showed that
more than 80% of the surveyed hospitals had implemented
maternal bacteriological screening and intrapartum chemo-
prophylaxis,10 possibly leading to a reduction in neonatal
early-onset disease. Guidelines for intrapartum antimicrobial
prophylaxis were recently issued by the Japanese Society of
Obstetrics and Gynecology (2008). These guidelines recom-
mend universal vaginal screening at 33—37 gestational weeks
and intrapartum prophylaxis for all culture-positive pregnant
women. Second, this is because of a real increase in the
absolute number of adult patients. In this study, we found an
approximately 2.8-fold increase from the first 5-year period
(1998—2002) to the second 5-year period (2003—2007).
Although a similar trend has been observed in other coun-
tries,3—7,16,17 such an increase is drastic when compared to
that of a US population-based study showing a 1.5-fold
increase between 1999 and 2005.7 However, since our esti-
mate is based on a single institution, the precise change in
the incidence among adult patients awaits a larger study.
The increasing rate of adult invasive GBS disease is also
partly because of an expanding population of adults who are
living longer with significant medical conditions. According to
the findings of our study and of several other studies,3—7,17—20
themost significant underlying condition is diabetes mellitus.
In Japan, the incidence of diabetes has been increasing
explosively; the estimated population of diabetic patients
plus candidates for diabetes increased from 13.7 million in
1997 to 18.7 million in 2006.21 Additionally, of note is our
finding that of the diabetic patients tested, more than three-
fourths had HbA1c levels of 8.0% or more. To our knowledge,
this is the first study describing the diabetic control status in
patients with GBS invasive disease. Thus, along with diabetes
itself, poorly controlled diabetes may be a risk factor for
invasive GBS disease.
The clinical presentation in infants was limited to bac-
teremia or meningitis. In contrast, manifestations in adult-
hood were numerous and varied. In our study, and in support
of previous findings,3—5,14,18—20 skin/soft tissue infections
and bacteremia were the most frequent clinical diagnosis.
Skin/soft tissue infections mostly presented as cellulitis and
decubitus, and the majority of these were complications
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related to being bedridden, others showed acquired disease
after a recent trauma or burn. In adult patients with bacter-
emia, the majority (63%) did not show any disease focus,
similar to the findings in previous reports.3—7,14—20
We found that the case fatality rates for patients overall
(16%) and for bacteremic patients (33%) were substantial,
comparable to those of recent studies.3,5—7,18—20 However,
we did not find a significant difference in the presence of
underlying condition or age, as observed in other stu-
dies.5,7,20 Bacteremic patients were significantly more fre-
quently associated with fatality compared to non-bacteremic
patients. Along with mortality, it is important to note that
amputation at the knee, ankle, or toes was performed in six
diabetic adults with skin/soft tissue infections. This is con-
cordant with the findings of Lee et al., who showed that eight
(11%) of 71 non-pregnant adults with GBS soft tissue infec-
tions eventually underwent amputation.22 These findings
highlight the importance of skin/soft tissue infections as a
risk factor for amputation. Prompt identification of groups at
greater risk coupled with early intervention will reduce the
mortality and morbidity associated with GBS infection.
A recent population-based study in the USA showed that
types Ia, Ib, II, III, and V accounted for 96% of neonatal cases
and the highest frequency was type III, while these types
comprised 88% of adult cases and the highest frequency was
type V.7 In contrast, our findings indicate that type Ib was the
most frequent pathogen followed by type III, and that types
Ia—Vaccounted for 69% of adult cases. The serotype distribu-
tion in Japan is unique.1,8,9 There was one patient demon-
strating type VI, who presented with toxic shock-like
syndrome. In addition, two patients demonstrating type VIII
showed early-onset neonatal sepsis and adult bacteremia.
Thus, these two serotypes have virulence for humans with a
clinical presentation similar to that of the more common
serotypes Ia—V. New preventive strategies using polysacchar-
ide—protein conjugate vaccine have been developed and the
vaccine’s safety and immunogenicity have been evaluated.7
However, our findings indicate that a pentavalent conjugate
vaccine including serotypes Ia, Ib, II, III, and V that is being
prepared in the USA would have lower potential for prevent-
ing invasive GBS disease in Japan. A more potent vaccine that
includes types VI and VIII is warranted.
Despite increasing antibiotic use, all isolates tested were
susceptible to penicillin, ampicillin, and vancomycin, and 2%
and 3% were resistant to erythromycin and clindamycin,
respectively. These findings confirm our previous results on
GBS isolates from pregnant women.8 However, Kimura et al.
have recently characterized reduced penicillin susceptible
strains, showing substitution of a few amino acids in penicillin
binding protein 2.23 To date, these reduced susceptible strains
have been isolated exclusively from non-sterile sites in adult
patients.23 Furthermore, 31% of strains in our series were
resistantto levofloxacin.Thisfigure is relativelyhighcompared
to the prevalence in North America and Europe.24,25 Taken
together, it seems important to continuously monitor the
susceptibility of invasive isolates throughout all age groups.
In conclusion, this study provides useful information on
invasive GBS disease in Japan. However, given that this study
was not population-based, the interpretation of the results
potentially includes some regional or institutional biases.
Therefore, a nationwide or population-based study shouldbe performed to determine precisely the epidemiology of
invasive GBS disease in Japan.
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